Abstract

Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. The aim of the current retrospective study was to compare transplantation outcomes of acute myeloid leukemia (AML) patients given UCBT after either RIC or MAC. Data from 894 adults with AML receiving a single or double UCBT as first allograft from 2004 to 2013 at EBMT centers were included in this study. 415 patients were given UCBT after RIC while 479 patients following a MAC. In comparison to MAC recipients, RIC recipients had a similar incidence of neutrophil engraftment and of acute and chronic graft-versus-host disease (GVHD). However, RIC recipients had a higher incidence of disease relapse and a lower NRM, translating to comparable leukemia-free (LFS), GVHD-free, relapse-free survival (GRFS) and overall survival (OS). These observations remained qualitatively similar after adjusting for differences between groups in multivariate analyses. In conclusion, these data suggest that LFS and OS are similar with RIC or with MAC in adults AML patients transplanted with UCBT. These observations could serve as basis for a future prospective randomized study.

Highlights

  • Allogeneic hematopoietic stem cell transplantation from human leukocyte antigen (HLA)-identical sibling is the treatment of choice for selected patients with acute myeloid leukemia (AML) [1,2,3]

  • In the last decade, reduced-intensity conditionings (RIC) for unrelated cord blood transplantation (UCBT) have been developed with the aim of reducing nonrelapse mortality (NRM) and allowing older/unfit patients to benefit from UCBT [6,7,8,9]

  • The impact of dose intensity on outcomes in AML patients has been the focus of many studies since the development of non-myeloablative/RIC regimens in the last 2 decades [13,14,15,16,17,18]

Read more

Summary

INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (allo-HCT) from HLA-identical sibling is the treatment of choice for selected patients with acute myeloid leukemia (AML) [1,2,3]. A recent study demonstrated low NRM after RIC UCBT for AML [10], a high incidence of disease relapse has been observed with this approach [10,11,12].

RESULTS
DISCUSSION
CONFLICTS OF INTERESTS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call